Minnesota Oncology
Latest Clinical News

FDA Approves Beleodaq for Peripheral T-cell Lymphoma (07-24-2014)

The FDA announces its approval of Beleodaq (belinostat), a histone deacetylase inhibitor for treating peripheral T-cell lymphoma (PTCL), based on the results of the BELIEF study that found an overall response rate of nearly 26% among treated patients. PTCL... Continue Reading

HPV Testing Found to Be More Effective Than Pap Smears in Evaluating Cervical Cancer Risk (07-23-2014)

Researchers at the National Cancer Institute reported that testing for HPV (human papillomavirus) is the most effective way to determine whether a woman is at risk for developing cervical cancer in the near future. Specifically, the study found that negative... Continue Reading

Revlimid, Velcade, and Dexamethasone Followed by Revlimid Maintenance Appears Promising (07-22-2014)

Researchers from France recently published the preliminary results of a clinical trial evaluating chemotherapy induction and consolidation treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (RVD) followed by Revlimid maintenance... Continue Reading

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment (07-21-2014)

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood... Continue Reading

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival (07-10-2014)

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (gemcitabine).... Continue Reading

TAS-102 Improves Survival in Advanced Colorectal Cancer (07-9-2014)

Researchers recently reported that the new combination agent TAS-102 improves overall survival in patients whose metastatic colorectal cancer is refractory to standard therapies. These results were recently reported at the ESMO 16th World Congress on... Continue Reading

Trial Evaluating Nivolumab in Advanced Melanoma Halted Early Because of Superior Results (07-8-2014)

Bristol-Myers Squibb announced on Tuesday that its clinical trial evaluating cancer immunotherapy nivolumab, which is being developed in advanced melanoma was halted early after it was determined that the drug was likely to prolong survival. Nivolumab... Continue Reading

Recent Study Finds That African American Women Less Likely To Receive Standard Breast Cancer Treatment (07-7-2014)

New research from the The University of Texas MD Anderson Cancer Center found that African American women diagnosed with early stage invasive breast cancer were 12 percent less likely than Caucasian women with the same diagnosis to receive axillary sentinel... Continue Reading

More Effective Colorectal Cancer Prevention with Colonoscopy Doctor with High Rate of Polyp Detection (07-3-2014)

Recent findings suggest that for more effective colorectal cancer prevention, it’s best to choose a physician for colonoscopy with a higher rate of precancerous polyp detection; meaning that he or she detects more polyps than colleagues in proportion... Continue Reading

Study Shows Polypectomy as Effective as Partial Colon Resection (07-2-2014)

A team from Stony Brook University reported that patients requiring removal of colon polyps could be effectively treated with laparoscopic-assisted polypectomy (LACP) and that the procedure required fewer resources than did partial colon resection (laparoscopic... Continue Reading

Aspirin Reduces Risk of Pancreatic Cancer (07-1-2014)

The results of a recent study suggest that regular aspirin use reduces the risk of pancreatic cancer by half.  Clinical studies have also found that regular aspirin use can reduce the risk for colon, esophageal, lung and prostate cancers, as well as... Continue Reading

Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy (07-1-2014)

A follow up report on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study of Abraxane® (nab-paclitaxel) in combination with Gemzar® (gemcitabine) in previously untreated patients with metastatic pancreatic cancer... Continue Reading

Next Page »